Union Minister Jitendra Singh Inaugurates Rs 600 Crore Pharma Facility in Kathua
In a significant move to bolster India's pharmaceutical self-reliance, Union Minister of State Jitendra Singh laid the foundation stone for a state-of-the-art Rs 600 crore pharmaceutical manufacturing facility in Kathua district, Jammu and Kashmir, on Saturday. This strategic project aims to enhance domestic production of critical antibiotic intermediates and reduce the nation's import dependence, particularly on China.
Key Details of the Kathua Pharmaceutical Plant
The facility, located in village Gadadhar, is being established by Orchid Pharma with support from the Biotechnology Industry Research Assistance Council (BIRAC), under the Department of Biotechnology. It will focus on manufacturing Amino Cephalosporanic Acid (ACA), a vital intermediate used in producing cephalosporin antibiotics, which are essential for treating bacterial infections.
Minister Singh emphasized that this investment, facilitated under the government's Production-Linked Incentive (PLI) Scheme, underscores growing confidence in Jammu and Kashmir's industrial and innovation potential. He projected that the plant will generate direct employment for approximately 400 individuals, with an additional 400 indirect jobs in sectors like logistics, supply chains, and allied services.
Addressing National Vulnerabilities in Healthcare
Highlighting the urgency of this initiative, Singh pointed out that India currently relies almost entirely on imports of ACA from China, creating vulnerabilities in supply security, pricing stability, and healthcare access. "Antibiotics are foundational to modern healthcare, and the pandemic showed how dependence on a single geography for essential inputs can quickly become a national vulnerability," he stated.
The minister described the project as a breakthrough for the regional pharmaceutical sector, noting that Kathua has the potential to emerge as a significant pharmaceutical manufacturing hub due to its improving industrial infrastructure. He linked this effort to Prime Minister Narendra Modi's vision of making India self-reliant in critical healthcare technologies and pharmaceutical supply chains.
Broader Policy Initiatives and Future Prospects
In his address, Singh also referenced the newly announced Rs 10,000 crore Biopharma Shakti initiative from the Union Budget, aimed at strengthening India's biotechnology and biopharmaceutical ecosystem. He asserted that such advanced manufacturing units could position Kathua on India's pharmaceutical export map, expanding the country's capacity and ensuring the availability and affordability of essential medicines during global disruptions.
This development is expected to not only enhance India's strategic capabilities in pharmaceutical manufacturing but also contribute to national health security by mitigating risks associated with import dependencies. The project aligns with broader goals of import substitution and industrial growth in Jammu and Kashmir, marking a step forward in the region's economic transformation.
